Aviva
CRL icon

Aviva’s Charles River Laboratories CRL Stock Holding History

Aviva’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,069
Closed -$5.74M – 856
2024
Q4 		$5.74M Buy
31,069
+29,137
+1,508% +$5.61M 0.01% 519
2024
Q3 		$381K Sell
1,932
-8,241
-81% -$1.71M ﹤0.01% 844
2024
Q2 		$2.1M Buy
10,173
+8,233
+424% +$1.87M 0.01% 575
2024
Q1 		$526K Buy
1,940
+29
+2% +$6.92K ﹤0.01% 861
2023
Q4 		$452K Hold
1,911
– – ﹤0.01% 881
2023
Q3 		$375K Sell
1,911
-34
-2% -$6.98K ﹤0.01% 915
2023
Q2 		$409K Sell
1,945
-59,026
-97% -$11.7M ﹤0.01% 900
2023
Q1 		$12.3M Buy
60,971
+50,900
+505% +$11.5M 0.06% 432
2022
Q4 		$2.19M Sell
10,071
-20,994
-68% -$4.58M 0.01% 696
2022
Q3 		$6.11M Sell
31,065
-9,497
-23% -$2.05M 0.04% 537
2022
Q2 		$8.68M Buy
40,562
+7,940
+24% +$1.94M 0.05% 478
2022
Q1 		$9.26M Buy
32,622
+16,270
+99% +$5.02M 0.05% 449
2021
Q4 		$6.16M Sell
16,352
-7,435
-31% -$2.89M 0.03% 533
2021
Q3 		$9.82M Buy
23,787
+14,577
+158% +$6.05M 0.04% 401
2021
Q2 		$3.41M Buy
+9,210
New +$3.08M 0.01% 681

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aviva's CRL Position: Q1 2025 in Review

Aviva sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 31,069 shares — an estimated $5.74M sold.

Aviva first reported a position in CRL in Q2 2021 and held it in 15 quarters. The position peaked at $12.3M in Q1 2023. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Aviva reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Aviva sold 31,069 Charles River Laboratories shares in Q1 2025, an estimated $5.74M.
  • Aviva first reported a position in Charles River Laboratories in Q2 2021 and held it in 15 quarters.
  • Aviva's Charles River Laboratories position peaked at $12.3M in Q1 2023.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Aviva's 13F filing for Q1 2025, filed 15 May 2025.